Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Stopped no accrual
Conditions
- Blasts Under 5 Percent of Peripheral Blood White Cells
- Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level
- IDH2 Gene Mutation
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- DRUG: Enasidenib
- PROCEDURE: Hematopoietic Cell Transplantation
Sponsor
Roswell Park Cancer Institute
Collaborators